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Chemotherapy remains one of the most 
widely employed therapeutic options 
against malignant conditions but its effi-
cacy is limited and, especially in the case 
of solid tumors, it rarely exerts a fully cura-
tive activity. Immunotherapy is emerging 
as an alternative approach to treat cancer 
patients, but it is also curative in a limited 
fraction of cases. So far, only a few stud-
ies have investigated approaches to com-
bine chemotherapy and immunotherapy, 
mostly because these two forms of treat-
ment have long been viewed as antagonis-
tic strategies. In fact, as chemotherapeutic 
drugs often display a limited specificity, 
virtually all proliferating cells, including 
leukocytes, are susceptible to their cyto-
toxic effects. Thus, leukocytopenia is a 
common side effect of cytotoxic chemo-
therapy and constitutes one of the main 
reasons why chemotherapy and immu-
notherapy have long been considered as 
mutually, exclusive, if not antagonistic, 
treatment modalities.
Recent studies have challenged the 
assumption that chemotherapy is intrinsi-
cally detrimental for the efficacy of immu-
notherapy. This change in perspective 
may have a profound impact on cancer 
therapy, especially in view of the ever more 
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precise characterization of so-called “can-
cer-initiating cells” (CICs), which nowa-
days are considered to be responsible for 
setting off and sustaining tumor growth.1 
CICs are resistant to commonly used che-
motherapeutics, mainly due to (1) their 
location within a hypoxic niche; (2) their 
reduced proliferative rate; (3) an improved 
DNA repair capacity; and (4) the over-
expression of antiapoptotic molecules.2 
However, conventional chemotherapy 
may offer an unexpected opportunity to 
improve the efficacy of immunotherapy. 
Chemotherapy enhances indeed the sen-
sitivity of tumor cells to the cytotoxic 
activity of natural killer (NK) cells, γδ or 
CD8+ T lymphocytes. Thus, combining 
immunotherapy with chemotherapy may 
bring about significant clinical benefits to 
(at least a fraction of) cancer patients.3
Vγ9Vδ2 T cells, the major subset of 
circulating γδ T cells, are good candi-
dates for such a combinatorial approach 
to anticancer therapy, mainly due to 
their capacity to recognize target cells 
in a MHC-unrestricted way, to respond 
to phosphoantigens synthesized by the 
mevalonate pathway, and to exert robust 
antitumor effects.4 Physiological levels of 
phosphoantigens generally fail to stimulate 
the immune system, but malignant cells 
produce increased levels of such metabolic 
intermediates, making them susceptible to 
recognition and killing by Vγ9Vδ2 T cells. 
Accordingly, the administration of amino-
bisphosphonates such as zoledronate (oper-
ating as inhibitors of farnesyl pyrophosphate 
synthase) to cancer cells cause the accumu-
lation of endogenous isoprenoids, hence 
increasing their susceptibility to Vγ9Vδ2 
T-cell cytotoxicity, which is mediated by 
the perforin-granzyme, CD95/CD95 
ligand (CD95L), tumor necrosis factor 
(TNF)/TNF receptor (TNF/TNFR) and 
TNF-related apoptosis-inducing ligand 
(TRAIL)/TRAIL receptor (TRAILR) 
systems. Additional lines of evidence 
point to γδ T cells as to ideal candidates 
for combinatorial chemoimmunotherapy. 
In particular, (1) chemotherapy sensitizes 
differentiated malignant cell lines to the 
cytotoxic activity of Vγ9Vδ2 T cells;5 
(2) chemotherapy-induced anticancer 
immune responses in the mouse are strictly 
γδ T cell-dependent;6 and (3) zoledronate 
makes colon CICs susceptible to Vγ9Vδ2 
T-cell killing.7 Taken together, these obser-
vations predict that chemotherapy and γδ 
T cell-based immunotherapy may exert 
synergistic anticancer effects.
According to common beliefs, conventional anticancer chemotherapy is deleterious for the immune system. we have 
recently provided in vitro evidence indicating that conventional chemotherapy may potentiate, rather than impair, the 
long-term efficacy of γδ t cell-based anticancer immunotherapy.
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of DR5-specific monoclonal antibodies 
limited the cytotoxic activity of Vγ9Vδ2 
T cells in our model. Moreover, the kill-
ing of colon CICs by Vγ9Vδ2 T cells was 
significantly inhibited by natural killer 
group 2 member D (NKG2D)-targeting 
antibodies, but neither by antibodies spe-
cific for CD3 or the γδ T-cell receptor 
(TCR) nor by mevastatin, an inhibitor of 
3-hydroxy-3-methylglutaryl-coenzyme A 
reductase that prevents the accumulation 
of endogenous phosphoantigens. This 
indicates that Vγ9Vδ2 T cells kill chemo-
therapy-sensitized colon CICs through a 
mechanism that involves the interaction 
of TRAIL with DR5 and that of NKG2D 
with MICA/B or ULBPs (Fig. 1).
Previous studies have demonstrated 
that chemotherapy can render tumor cells 
of different origin susceptible to NK or 
T cell-mediated killing by upregulating 
the expression of death receptors, includ-
ing DR5.9 Our study provides the first 
evidence of DR5 upregulation on CICs, 
as this effect has previously been reported 
only for differentiated cancer cells. We are 
actually investigating whether the upregu-
lation of DR5 by chemotherapy is a gen-
eral phenomenon or is restricted to the 
CRC setting.
The idea of combining conventional 
chemotherapy with immunotherapy cur-
rently stands at a pre-clinical stage of 
development, mainly because these two 
approaches have long been considered to 
be mutually exclusive. Our study suggests 
that the activation of Vγ9Vδ2 T cells in 
vivo or the adoptive transfer of Vγ9Vδ2 
T cells activated ex vivo, along with or 
immediately after the administration of 
conventional chemotherapy may result in 
substantially increased therapeutic effects 
and hence provide consistent clinical ben-
efits to cancer patients. Properly designed 
clinical studies are required to understand 
the actual potential of this combinatorial 
chemoimmunotherapeutic regimen.
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ratios, while being highly cytotoxic for dif-
ferentiated CRC cell lines. Unexpectedly, 
the pre-incubation of colon CIC lines 
with 5-FU or doxorubicin sensitized them 
to the cytotoxic activity of allogeneic and 
autologous Vγ9Vδ2 T cell lines, mediat-
ing additive effects at low concentrations 
and almost complete lysis at high doses.
CIC lines constitutively express 
MHC class I molecules; intercellular 
adhesion molecule 1 (ICAM1); CD112; 
CD155; MHC class I polypeptide-related 
sequence (MIC)A/B; UL16-binding pro-
tein (ULBP)1–4; CD95, TNFR1 and 
death receptor (DR)4 (also known as 
TRAIL-R1), all of which were not upreg-
ulated by the administration of 5-FU and 
doxorubicin. Conversely, these chemo-
therapeutic agents significantly increased 
the expression levels of DR5 (TRAIL-R2) 
on colon CICs. Accordingly, the inhibition 
of the TRAIL/DR5 interaction by means 
We have recently tested this possibility 
in vitro by combining chemotherapy with 
Vγ9Vδ2 T cells to efficiently target colon 
CICs. In particular, since colon CICs are 
resistant to either of these therapeutic 
modalities employed as a standalone inter-
vention, we tested whether chemotherapy 
sensitizes colon CICs to the cytotoxic 
activity of Vγ9Vδ2 T cells.8
Thus, two antineoplastic agents that 
are largely employed in the treatment of 
CRC patients, namely, 5-fluorouracil 
(5-FU) and doxorubicin, failed to kill five 
different colon CIC lines over a 24–72 h 
treatment period, even when used at very 
high doses. Conversely, both 5-FU and 
doxorubicin exerted robust antineoplas-
tic effects against differentiated CRC 
cell lines. Along similar lines Vγ9Vδ2 
T cell lines obtained from CRC patients 
or healthy donors failed to kill colon CIC 
lines, even at high effector:target (E:T) 
Figure 1. Combinatorial antineoplastic effects of conventional chemotherapy and γδ t cell-based 
immunotherapy. Commonly used chemotherapeutic agents such as 5-fluorouracil (5-Fu) and 
doxorubicin (DXr) stimulate colon cancer-initiating cells to express increased amounts of death 
receptor 5 (Cr5), rendering them susceptible to the tNF-related apoptosis inducing ligand (trAIL) 
dependent cytotoxic activity of Vγ9Vδ2 t cells, following the natural killer group 2 member D 
(NKG2D)-dependent recognition of stress-induced ligands. MIC, MhC class I polypeptide-related 
sequence; uLBP, uL16-binding protein.
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